Characteristics and safety outcomes of rheumatoid arthritis patients treated with AMGEVITA® in the United Kingdom using data from a national register
Authors' conclusion
The crude incidence rates of SAEs and serious infections among AMGEVITA® users were within the range observed for the anti-TNF comparator cohort.
Study context
- Population
- Patients ≥16 years with rheumatoid arthritis (RA) in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA), UK, enrolled 01/01/2019 to 31/03/2022 (mean age 59.7 years; 28.0% male)
- Participants
- 288 AMGEVITA® initiators
- Exposure
- AMGEVITA® vs BSRBR-RA anti-tumor necrosis factor (anti-TNF) comparison cohort
- AMGEVITA®n = 288
- Outcome
- Serious adverse events (SAEs) (crude incidence rate)
Methodological detailsnational register (BSRBR-RA), interim pharmacovigilance report, descriptive statistics, Follow-up ended 30/11/2023
- National register (BSRBR-RA)
- Interim pharmacovigilance report
- Descriptive statistics
- Follow-up ended 30/11/2023
Main finding
As reported in the abstract
Crude SAE incidence rate
Observational data: associations, not effects.
Safety
Serious infections, crude incidence rate
Original publication
Characteristics and safety outcomes of rheumatoid arthritis patients treated with AMGEVITA® in the United Kingdom using data from a national register. Arthritis Res Ther. Published 21 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →